BioCentury
ARTICLE | Clinical News

Treakisym bendamustine: Completed Phase II enrollment

March 11, 2013 7:00 AM UTC

SymBio completed enrollment of 70 patients in an open-label, Japanese Phase II trial comparing Treakisym plus rituximab vs. R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubin, vincristine and...